Skip to Main Content

An official website of the United States government

About this Publication
Title
Serum immunoglobulin e and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Pubmed ID
24718282 (View this publication on the PubMed website)
Publication
Cancer Epidemiol. Biomarkers Prev. 2014 Jul; Volume 23 (Issue 7): Pages 1414-20
Authors
Olson SH, Hsu M, Wiemels JL, Bracci PM, Zhou M, Patoka J, Reisacher WR, Wang J, Kurtz RC, Silverman DT, Stolzenberg-Solomon RZ
Affiliations
  • Authors' Affiliations: Department of Epidemiology and Biostatistics; olsons@mskcc.org.
  • Authors' Affiliations: Department of Epidemiology and Biostatistics;
  • Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, California;
  • Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medical College, New York, New York;
  • Division of Pediatric Allergy and Immunology, Mt. Sinai Medical Center;
  • Department of Medicine, Memorial Sloan Kettering Cancer Center;
  • Occupational and Environmental Epidemiology Branch; and.
  • Branch of Nutritional Epidemiology, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland.
Abstract

Epidemiologic studies have consistently found that self-reported allergies are associated with reduced risk of pancreatic cancer. Our aim was to prospectively assess the relationship between serum immunoglobulin E (IgE), a marker of allergy, and risk. This nested case-control study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) included subjects enrolled in 1994 to 2001 and followed through 2010. There were 283 cases of pancreatic cancer and 544 controls matched on age, gender, race, and calendar date of blood draw. Using the ImmunoCAP system, we measured total IgE (normal, borderline, elevated), IgE to respiratory allergens, and IgE to food allergens (negative or positive) in serum collected at baseline. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using conditional logistic regression. We assessed interactions with age, gender, smoking, body mass index, and time between randomization and case diagnosis. Overall, there was no association between the IgE measures and risk. We found a statistically significant interaction by baseline age: in those aged ≥65 years, elevated risks were observed for borderline total IgE (OR, 1.43; 95% CI, 0.88-2.32) and elevated total IgE (OR, 1.98; 95% CI, 1.16-3.37) and positive IgE to food allergens (OR, 2.83; 95% CI, 1.29-6.20); among participants <65 years, ORs were <1. Other interactions were not statistically significant. The reduced risk of pancreatic cancer associated with self-reported allergies is not reflected in serum IgE.

Related CDAS Studies
Related CDAS Projects